Cargando…
Use of imaging modalities for decision-making in inflammatory bowel disease
Cross-sectional magnetic resonance enterography (MRE) and intestinal ultrasonography (IUS) provide valuable and noninvasive information to accurately assess disease activity, severity, and extent; detect complications; and monitor the response to treatment, as well as predict the postoperative recur...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912556/ https://www.ncbi.nlm.nih.gov/pubmed/36777362 http://dx.doi.org/10.1177/17562848231151293 |
_version_ | 1784885230841102336 |
---|---|
author | Nancey, Stéphane Fumery, Mathurin Faure, Mathias Boschetti, Gilles Gay, Claire Milot, Laurent Roblin, Xavier |
author_facet | Nancey, Stéphane Fumery, Mathurin Faure, Mathias Boschetti, Gilles Gay, Claire Milot, Laurent Roblin, Xavier |
author_sort | Nancey, Stéphane |
collection | PubMed |
description | Cross-sectional magnetic resonance enterography (MRE) and intestinal ultrasonography (IUS) provide valuable and noninvasive information to accurately assess disease activity, severity, and extent; detect complications; and monitor the response to treatment, as well as predict the postoperative recurrence of Crohn’s disease and a negative disease course. Therefore, both imaging modalities are emerging as pivotal diagnostic tools to achieve the emerging therapeutic target of transmural healing associated with better disease outcomes. Despite its numerous potential advantages over endoscopy and even MRE and its good availability, IUS is still widely underused to monitor and manage inflammatory bowel disease (IBD) patients and help in making clinical decisions in routine practice. This situation is clearly due to the absence of validated, reliable, and responsive indices, as well as the lack of trained gastroenterologists and radiologists, as IUS is a component of radiologist expertise in several countries but not yet integrated into the training program of gastroenterologists. However, there is an increasing body of evidence in the literature that IUS and MRE are both becoming essential imaging resources to help clinicians in making reliable decisions. Here, we discuss the up-to-date evidence about the usefulness and performance of cross-sectional imaging, focusing on the ability of bowel US and MRE to aid clinical decision-making for the optimal management and monitoring of IBD. |
format | Online Article Text |
id | pubmed-9912556 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-99125562023-02-11 Use of imaging modalities for decision-making in inflammatory bowel disease Nancey, Stéphane Fumery, Mathurin Faure, Mathias Boschetti, Gilles Gay, Claire Milot, Laurent Roblin, Xavier Therap Adv Gastroenterol Review Cross-sectional magnetic resonance enterography (MRE) and intestinal ultrasonography (IUS) provide valuable and noninvasive information to accurately assess disease activity, severity, and extent; detect complications; and monitor the response to treatment, as well as predict the postoperative recurrence of Crohn’s disease and a negative disease course. Therefore, both imaging modalities are emerging as pivotal diagnostic tools to achieve the emerging therapeutic target of transmural healing associated with better disease outcomes. Despite its numerous potential advantages over endoscopy and even MRE and its good availability, IUS is still widely underused to monitor and manage inflammatory bowel disease (IBD) patients and help in making clinical decisions in routine practice. This situation is clearly due to the absence of validated, reliable, and responsive indices, as well as the lack of trained gastroenterologists and radiologists, as IUS is a component of radiologist expertise in several countries but not yet integrated into the training program of gastroenterologists. However, there is an increasing body of evidence in the literature that IUS and MRE are both becoming essential imaging resources to help clinicians in making reliable decisions. Here, we discuss the up-to-date evidence about the usefulness and performance of cross-sectional imaging, focusing on the ability of bowel US and MRE to aid clinical decision-making for the optimal management and monitoring of IBD. SAGE Publications 2023-02-09 /pmc/articles/PMC9912556/ /pubmed/36777362 http://dx.doi.org/10.1177/17562848231151293 Text en © The Author(s), 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Nancey, Stéphane Fumery, Mathurin Faure, Mathias Boschetti, Gilles Gay, Claire Milot, Laurent Roblin, Xavier Use of imaging modalities for decision-making in inflammatory bowel disease |
title | Use of imaging modalities for decision-making in inflammatory bowel
disease |
title_full | Use of imaging modalities for decision-making in inflammatory bowel
disease |
title_fullStr | Use of imaging modalities for decision-making in inflammatory bowel
disease |
title_full_unstemmed | Use of imaging modalities for decision-making in inflammatory bowel
disease |
title_short | Use of imaging modalities for decision-making in inflammatory bowel
disease |
title_sort | use of imaging modalities for decision-making in inflammatory bowel
disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9912556/ https://www.ncbi.nlm.nih.gov/pubmed/36777362 http://dx.doi.org/10.1177/17562848231151293 |
work_keys_str_mv | AT nanceystephane useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease AT fumerymathurin useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease AT fauremathias useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease AT boschettigilles useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease AT gayclaire useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease AT milotlaurent useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease AT roblinxavier useofimagingmodalitiesfordecisionmakingininflammatoryboweldisease |